The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Li-Fraumeni syndrome – a molecular and clinical review
Open accessAbstract
In 1969 Li and Fraumeni identified, from a systematic study of 648 children with rhabdomyosarcomas, five families in which a sibling or a cousin was affected by sarcoma (Li and Fraumeni, 1969a, b). A prospective study of four of the original families indicated that there was a significantly increased risk of cancer within these families, particularly premenopausal breast cancer, as well as a significant excess of second malignancies (Li and Fraumeni, 1982). The term 'Li-Fraumeni syndrome' was used initially by Pearson et al (1982) and is now the most common term for this dominant inherited cancer syndrome. Studies from our own group on a population-based series of children with soft-tissue sarcoma (Birch et al, 1984; 1990) and a USA hospital-based series of survivors of childhood soft-tissue sarcomas from Strong's group in the USA (Strong et al, 1987) confirmed that the familial clustering was due to inherited predisposition and not to environmental factors. Twenty-four families, defined using strict criteria, were subsequently studied by the Li and Fraumeni groups (Li et al, 1988). Such families are now regarded as having 'classic' Li-Fraumeni syndrome (LFS), namely a proband aged under 45 years with a sarcoma having a first-degree relative aged under 45 years with any cancer and an additional firstor second-degree relative aged under 45 years in the same lineage with any cancer or a sarcoma at any age (Li et al, 1988). This study by Li et al (1988) indicated that the spectrum of tumours within the syndrome included acute leukaemia, premenopausal breast carcinoma, brain and adrenocortical tumours as well as bone and soft-tissue sarcomas. Other studies have indicated that a number of other cancers may occur at an increased frequency in these families, notably melanoma, germ cell tumours, Wilms' tumours, gastric and pancreatic carcinomas and lung cancer (Hartley et al, 1987; 1989; Strong et al, 1987; Varley et al, 1995; 1997a). While the definition of classic LFS has become generally accepted, a number of groups have relaxed the description to include incomplete Li-Fraumeni syndrome (a proband with an affected first-degree relative; Brugieres et al, 1993) and LiFraumeni-like syndrome (LFL). Two groups have defined LFL families independently but using different criteria. Eeles (1995) defined LFL as a clustering of two different tumours (both characteristic of LFS) in individuals who are firstor second-degree relatives of any age. Our own group has defined LFL by more stringent criteria: a proband with any childhood tumour or sarcoma, brain tumour or adrenocortical tumour under 45 years plus a firstor second-degree relative with a typical LFS tumour at
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Expression of recessive alleles by chromosomal mechanisms in retinoblastoma
Cavenee, W. K., Dryja, T. P., Phillips, R. A., Benedict, W. F., Godbout, R., Gallie, B. L., Murphree, A. L., Strong, L. C., & White, R. L. (1983) · Nature · doi:10.1038/305779a0 · Cited by 1,920
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients
Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N. C., Lynch, H. T., Watson, P., Jass, J. R., Dunlop, M., Wyllie, A., Peltomäki, P., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-169 · Cited by 945
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 730
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
Eliyahu, D., Raz, A., Gruss, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 717
A p53-Dependent Mouse Spindle Checkpoint
Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., & Reid, B. J. (1995) · Science · doi:10.1126/science.7871434 · Cited by 660
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Structural aspects of the p53 protein in relation to gene evolution.
Soussi, T., de Fromentel, C. C., & May, P. (1990) · PubMed · Cited by 603
A subset of p53-deficient embryos exhibit exencephaly
Sah, V. P., Attardi, L. D., Mulligan, G. J., Williams, B. O., Bronson, R. T., & Jacks, T. (1995) · Nature Genetics · doi:10.1038/ng0695-175 · Cited by 580
p53 mutations increase resistance to ionizing radiation.
Lee, J. M., & Bernstein, A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5742 · Cited by 564
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53
Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 552
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation
Hollstein, M. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.141 · Cited by 499
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
Birch, Hartley, Tricker, Prosser, P., Condie, Kelsey, Harris, Jones, Binchy, Crowther, et al. (1994) · Cancer Research · Cited by 475
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
Birch, J. M., Hartley, A. L., Tricker, K. J., Prosser, J., Condie, A., Kelsey, A. M., Harris, M., Jones, P. H. M., Binchy, A., & Crowther, D. (1994) · PubMed · Cited by 421
Self-citationSmith, S. A., Easton, D. F., Evans, D. G. R., & Ponder, B. A. J. (1992) · Nature Genetics · doi:10.1038/ng1092-128 · Cited by 411
Self-citationRhabdomyosarcoma in Children: Epidemiologic Study and Identification of a Familial Caneer Syndrome
(1969) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/43.6.1365 · Cited by 397
Lavigueur, A., Maltby, V, Mock, D., Rossant, J., Pawson, T., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 394
Malkin, D., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., Andersen, T. I., Børresen, A.-L., Li, F. P., Garber, J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262002 · Cited by 379
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
Kemp, C. J., Wheldon, T., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 368
Ford, J. M., & Hanawalt, P. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8876 · Cited by 346
High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR
Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., & Gronenborn, A. M. (1994) · Science · doi:10.1126/science.8023159 · Cited by 307
Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma
Toguchida, J., Yamaguchi, T., Dayton, S. H., Beaughamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262001 · Cited by 307
Evidence for a second cell cycle block at G2/M by p53.
Stewart, N., Hicks, G. G., PARASKEVAS, F., & Mowat, M. R. A. (1995) · PubMed · Cited by 300
Ponder, B. (1988) · Nature · doi:10.1038/335400a0 · Cited by 277
Bischoff, F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella, B. C., Strong, L. C., & Tainsky, M. A. (1990) · PubMed · Cited by 252
Rogan, E. M., Bryan, T. M., Hukku, B., Maclean, K., Chang, A. C.-M., Moy, E. L., Englezou, A., Warneford, S. G., Dalla-Pozza, L., & Reddel, R. R. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4745 · Cited by 250
Inherited p53 gene mutations in breast cancer.
Sidransky, D., Tokino, T., Helzlsouer, K. J., et al. (1992) · PubMed · Cited by 249
Prospective Study of a Family Cancer Syndrome
Li, F. P. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320440040031 · Cited by 244
Screening patients for heterozygous p53 mutations using a functional assay in yeast
Ishioka, C., Frebourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
Diller, L., Sexsmith, E., Gottlieb, A., Li, F. P., & Malkin, D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117834 · Cited by 220
Germline mutations in the TP53 gene.
Eeles, R. A. (1995) · PubMed · Cited by 211
Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.
Frébourg, T., Barbier, N., Yan, Y.-X., Garber, J. E., Dreyfus, M., Fraumeni, J. F., Li, F. P., & Friend, S. H. (1995) · Europe PMC (PubMed Central) · Cited by 202
Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.
McIntyre, J. F., Smith-Sorensen, B., Friend, S. H., Kassell, J., Borresen, A. L., Yan, Y. X., Russo, C., Sato, J., Barbier, N., & Miser, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.925 · Cited by 200
Heyn, R., Haeberlen, V, Newton, W. A., Ragab, A. H., Raney, R. B., Tefft, M., Wharam, M., Ensign, L. G., & Maurer, H. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.262 · Cited by 192
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient
Barnes, D. M., Gillett, C. E., Bobrow, L. G., Hanby, A. M., Mohammed, S., Hodgson, S., Leigh, I. M., Purkis, T., MacGeoch, C., Spurr, N. K., et al. (1992) · The Lancet · doi:10.1016/0140-6736(92)92354-i · Cited by 190
Screening for germ line TP53 mutations in breast cancer patients.
Børresen‐Dale, A., Andersen, T. I., Garber, J. E., Barbier, N., Thorlacius, S., Eyfjord, J. E., Ottestad, L., Smith‐Sørensen, B., Hovig, E. J., & Malkin, D. M. (1992) · PubMed · Cited by 187
Mammalian p53 can function as a transcription factor in yeast
Schärer, E., & lggo, R. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.7.1539 · Cited by 177
Defective G2 checkpoint function in cells from individuals with familial cancer syndromes.
Paules, R. S., Levedakou, E. N., Wilson, S. J., Innes, C. L., Rhodes, N., Tlsty, T. D., Galloway, D. A., Donehower, L. A., Tainsky, M. A., & Kaufmann, W. K. (1995) · PubMed · Cited by 169
The cellular oncogene p53 can be activated by mutagenesis
Jenkins, J. R., Rudge, K., Chumakov, P., & Currie, G. A. (1985) · Nature · doi:10.1038/317816a0 · Cited by 169
Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13.
Guðmundsson, J., Jóhannesdóttir, G., Bergþorsson, J. Þ., Arason, A., Ingvarsson, S., Egilsson, V., & Barkardottir, R. B. (1995) · PubMed · Cited by 156
Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.
Lustbader, E. D., Williams, W. R., Bondy, M. L., Strom, S. S., & Strong, L. C. (1992) · PubMed · Cited by 148
Shay, J. W., Tomlinson, G. E., Piatyszek, M. A., & Gollahon, L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.425 · Cited by 145
Cancer in Survivors of Childhood Soft Tissue Sarcoma and Their Relatives
Strong, L. C., Stine, M. D., & Norsted, T. L. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.6.1213 · Cited by 141
Inherited susceptibility to breast cancer.
Easton, D. F., Ford, D., & Peto, J. (1993) · PubMed · Cited by 140
Germline p53 Gene Mutations in Subsets of Glioma Patients
Kyritsis, A. P., Bondy, M. L., Xiao, M., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.5.344 · Cited by 133
TP53 Gene Mutations and 17p Deletions in Human Astrocytomas
Chung, R. Y., Whaley, J. M., Kley, N., Anderson, K., Louis, D. N., Menon, A. G., Hettlich, C., Freiman, R. N., Hedley‐Whyte, E. T., Martuza, R. L., et al. (1991) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870030502 · Cited by 132
Recommendations on Predictive Testing for Germ Line p53 Mutations Among Cancer-Prone Individuals
Li, F. P., Garber, J. E., Friend, S. H., Strong, L. C., Patenaude, A. F., Juengst, E. T., Reilly, P. R., Correa, P., & Fraumeni, J. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.15.1156 · Cited by 126
Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice.
Bouffler, S. D., Kemp, C. J., Balmain, A., & Cox, R. (1995) · PubMed · Cited by 121
Ichii, S., Horii, A., Nakatsuru, S., Furuyama, J.-I., Utsunomiya, J., & Nakamura, Y. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.387 · Cited by 119
Lee, J. M., Abrahamson, J., Kandel, R., Donehower, L. A., & Bernstein, A. (1994) · PubMed · Cited by 115
Harris, C. C. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.47 · Cited by 107
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.
Felix, C. A., Nau, M. M., Takahashi, T., Mitsudomi, T., Chiba, I., Poplack, D., Reaman, G. H., Cole, D. E., Letterio, J. J., & Whang‐Peng, J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115630 · Cited by 91
Sameshima, Y., Tsunematsu, Y., Watanabe, S., Tsukamoto, T., Kawa‐Ha, K., Hirata, Y., Mizoguchi, H., Sugimura, T., Terada, M., & Yokota, J. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.9.703 · Cited by 91
New insights into p53 function from structural studies.
Arrowsmith, C. H., & Morin, P. J. (1996) · PubMed · Cited by 91
The p53 gene in pediatric therapy-related leukemia and myelodysplasia
Felix, C., Hosler, M. R., Provisor, D., Salhany, K., Sexsmith, E., Slater, D., Cheung, N., Winick, N., Strauss, E., Heyn, R. M., et al. (1996) · Blood · doi:10.1182/blood.v87.10.4376.bloodjournal87104376 · Cited by 80
p53 deficiency does not affect the accumulation of point mutations in a transgene target.
Sands, A., Suraokar, M. B., Sánchez, A. P., Marth, J. D., Donehower, L. A., & Bradley, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8517 · Cited by 80
A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families
Porter, D. E., Holden, S., Steel, C., Bb, C., Wallace, M., & Reid, R. (1992) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.74b6.1447251 · Cited by 75
Excess risk of breast cancer in the mothers of children with soft tissue sarcomas
Birch, J. M., Hartley, A. L., Marsden, H. B., Harris, M., & Swindell, R. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.51 · Cited by 74
Self-citationAre germ cell tumors part of the Li-Fraumeni cancer family syndrome?
Hartley, A. L., Birch, J. M., Kelsey, A. M., et al. (1989) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(89)90090-3 · Cited by 74
Self-citationConstitutional p53 mutations associated with brain tumors in young adults
Chen, P., Iavarone, A., Fick, J. R., Edwards, M. S. B., Prados, M., & Israel, M. A. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00213-u · Cited by 71
Brugières, L., Gardes, M., Moutou, C., Chompret, A., Méresse, V., Martin, A., Poisson, N., Flamant, F., Bonaïti‐Pellié, C., & Lemerle, J. (1993) · PubMed · Cited by 71
A functional screen for germ line p53 mutations based on transcriptional activation.
Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 67
Nishino, H., Knöll, A., Buettner, V. L., Frisk, C. S., Maruta, Y., Haavik, J., & Ss, S. (1995) · PubMed · Cited by 66
Bihan-Benjamin, C. L., Moutou, C., Brugières, L., Feunteun, J., & Bonaïti‐Pellié, C. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120103 · Cited by 61
TRANSMISSION OF IN-VITRO RADIORESISTANCE IN A CANCER-PRONE FAMILY
Bech‐Hansen, N. T., Sell, B. M., Lampkin, B. C., Blattner, W. A., Mckeen, E., Fraumeni, J., & Paterson, M. C. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92517-4 · Cited by 60
Incidence of germ‐line p53 mutations in patients with gliomas
Li, Y., Sanson, M., Hoang‐Xuan, K., Delattre, J., Poisson, M., Thomas, G. D., & Hamelin, R. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640606 · Cited by 60
Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu, P. K., Kraus, E., Wu, T., Strong, L. C., & Tainsky, M. A. (1996) · PubMed · Cited by 59
Birch, J. M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00383-g · Cited by 57
Self-citationConstitutional p53 mutation in a non-Li-Fraumeni cancer family
Prosser, J., Porter, D., Coles, C., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.109 · Cited by 56
Two families with the Li-Fraumeni cancer family syndrome
Pearson, A., Craft, A. W., Ratcliffe, J. M., et al. (1982) · Journal of Medical Genetics · doi:10.1136/jmg.19.5.362 · Cited by 49
Birch, J. M., Heighway, J., Teare, M. D., Kelsey, A. M., Hartley, A. L., Tricker, K. J., Crowther, D., Lane, D. P., & Santibanez‐Koref, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.468 · Cited by 49
Self-citationHorio, Y., Suzuki, H., Ueda, R., Koshikawa, T., Sugiura, T., Ariyoshi, Y., Shimokata, K., Takahashi, T., & Takahashi, T. (1994) · PubMed · Cited by 41
Mammalian p53 can function as a transcription factor in yeast
Iggo, R. D., & Schärer, E. (1992) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(92)90407-y · Cited by 37
Camplejohn, R., Perry, P., Hodgson, S. V., Turner, G. S., Williams, A. C., Upton, C., MacGeoch, C., Mohammed, S. N., & Barnes, D. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.390 · Cited by 37
A novel p53 germline alteration identified in a late onset breast cancer kindred.
Sun, X. F., Jóhannsson, Ó. Þ., Håkansson, S., et al. (1996) · PubMed · Cited by 35
Familial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236
Lübbe, J., Ammon, K. V., Watanabe, K., Hegi, M. E., & Kleihues, P. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00572.x · Cited by 32
Hartley, A. L., Birch, J. M., Marsden, H. B., et al. (1987) · Journal of Medical Genetics · doi:10.1136/jmg.24.11.664 · Cited by 31
Self-citationA novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm.
Felix, C. A., Strauss, E. A., D'Amico, D., Tsokos, M., Winter, S. C., Mitsudomi, T., Nau, M. M., Brown, D., Leahey, A., & Horowitz, M. (1993) · PubMed · Cited by 31
Tsutsui, T., Fujino, T., Kodama, S., Tainsky, M. A., Boyd, J. A., & Barrett, J. C. (1995) · Carcinogenesis · doi:10.1093/carcin/16.1.25 · Cited by 26
A de novo p53 germline mutation affecting codon 151 in a six year old child with multiple tumors
Gutiérrez, M. I., Bhatla, K. G., Berreiro, C., Spangler, G., Schvartzman, E., Muriel, F. S., & Magrath, L. T. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.12.2247 · Cited by 23
Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation.
Lalle, P., Moyret‐Lalle, C., Wang, Q., Vialle, J.-M., Navarro, C., Paillerets, B. B., Magaud, J., & Öztürk, M. (1995) · PubMed · Cited by 21
Gh, G., Moore, S. L., Schneider, B., Saldivar, & Hensel, C. H. (1994) · PubMed · Cited by 21
Plummer, S. J., Santibanez‐Koref, M., Kurosaki, T., Liao, S., Noble, B., Fain, P. R., Anton‐Culver, H., & Casey, G. (1994) · PubMed · Cited by 20
Speiser, P., Gharehbaghi-Schnell, E., Eder, S., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.350 · Cited by 17
Complex replication error causes p53 mutation in a Li-Fraumeni family.
Strauss, E. A., Hosler, M. R., Herzog, P., Salhany, K., Louie, R., & Felix, C. A. (1995) · PubMed · Cited by 16
No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines
Williams, K. J., Heighway, J., Birch, J. M., Norton, J. D., & Scott, D. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.424 · Cited by 14
Self-citationSingle base pair germ-line deletion in the p53 gene in a cancer predisposed family
Hamelin, R., Barichard, F., Henry, I., Junien, C., & Thomas, G. D. (1994) · Human Genetics · doi:10.1007/bf02272849 · Cited by 13
Varley, J. M., Thorncroft, M. R., McGown, G., Tricker, K. J., Birch, J. M., & Evans, D. G. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(96)00059-3 · Cited by 13
Self-citationStolzenberg, M., Brugières, L., Gardes, M., Dessarps-Freichey, F., Chompret, A., Paillerets, B. B., Lenoir, G., Bonaïti‐Pellié, C., Lemerle, J., & Feunteun, J. (1994) · PubMed · Cited by 13
Cited by
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
Self-citationRubbi, C. P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg579 · Cited by 811
Metadata
- Authors
- Varley, J., Evans, D., & Birch, J.
- Venue
- British Journal of Cancer
- Published
- 1997-07
- Volume
- 76
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2003090246
- Cited by
- 358
- References
- 111
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.